

### **Bristol-Myers Squibb Company** P.O. Box 4000 Princeton, NJ 08543-4000 U.S.A.

DEC 13 2005



To:	COMMISSIONER FOR PATENTS Examiner Raymond K. Covington Art Group: 1625	From:	Aldo A. Algieri Reg. No. 31,697	٠.
Fax;	571-273-8300	Phone:	203-677-6809	
Date:	December 13, 2005	Pages:	24, including cover page	
Re:	USSN 10/719,187	Docket:	CT2717 - US - NP	

The following documents are enclosed:

- (1) Amendment and Reply Under Rule 37 CFR 1.111 (5 pages)
- [2] Amended Claims [3 pages]
- (3) Information Disclosure Statement [1 page with copy]
- (4) PTO-1449 [1 page]
- [5] Reference [12 pages]

#### CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that the documents listed above are being transmitted via facsimile to the United States Patent and Trademark Office on \_\_\_\_\_

Nancy S. Turover

PAGE 1/16 \* RCVD AT 12/13/2005 3:53:32 PM [Eastern Standard Time] \* SVR:USPTO-EFXRF-6/26 \* DNIS:2738300 \* CSID:2036776900 \* DURATION (mm-ss):09-20

CASE CT-2717 US - NP

RECEIVED CENTRAL FAX GENTER

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

DEC 1 3 2005

IN RE APPLICATION OF Wu, et al.

EXAMINER: Raymond K. Covington

APPLICATION NO: 10/719,187

ART UNIT: 1625

FILED: November 21, 2003

FOR: 3-HETEROCYCLIC BENZYLAMIDE DERIVATIVES AS POTASSIUM

**CHANNEL OPENERS** 

VIA FACSIMILE: 571-273-8300

Commissioner for Patents

P.O. Box1450,

Alexandria, VA 22313-1450

# AMENDMENT AND REPLY UNDER RULE 37 C.F.R. §1.111

Sir:

A shortened statutory period for response to the outstanding Office Action mailed October 24, 2005, is due January 24, 2006.

Applicant respectfully traverse the rejections and kindly request reconsideration based on the following amendments and remarks.

#### IN THE CLAIMS

Claims 1 - 4 and 6 - 8 remain in the application. Claim 6 is amended,

Kindly amend claim 6 by deleting "and neurodegenerative disorders". Also, please insert "and" after the word anxiety and before the word depression.